Global Influenza Vaccines Market Outlook 2018-2028

インフルエンザワクチンの世界市場

◆タイトル:Global Influenza Vaccines Market Outlook 2018-2028
◆商品コード:VGN808048
◆調査・発行会社:visiongain
◆発行日:2018年6月
◆ページ数:138
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle UserGBP3,499 ⇒換算¥475,864見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥530,264見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥679,864見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、インフルエンザワクチンの世界市場について調査・分析し、インフルエンザワクチンの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW.

In this brand new 138-page report you find 63 in-depth tables, charts and graphs – all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
• Trivalent Influenza Vaccines (TIV)
• Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:
• Sanofi Pasteur
• GSK
• Seqirus
• AstraZeneca
• Protein Science Corporation.
• Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal Influenza vaccines in development
• Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:
• Fluzone / VaxiGrip
• Seqirus
• Fluarix / FluLaval
• FluMist / Fluenz
• FluBlok
• Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:
• United States
• Japan
• The EU 5 – Germany, France, United Kingdom, Italy and Spain.
• Brazil, Russia, India and China

Global Influenza Vaccines Market Outlook 2018-2028

Who should read this report?
• Anyone within the influenza vaccines value chain.
• Pharmaceutical companies
• Vaccine manufacturers
• Healthcare biotech companies
• Generics and biosimilar producers
• Drug delivery companies and other technology providers
• Contract/clinical research organisations (CROs)
• Pharma contract manufacturers,
• Pharma/healthcare wholesale and distribution companies
• Medical device companies
• Healthcare diagnostics companies
• R&D specialists
• Business development managers
• Marketing managers
• Technologists
• Suppliers
• Investors
• Banks
• Government agencies
• Contractors

Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.

【レポートの目次】

1. Report Overview

1.1 Global Influenza Vaccine Market Overview

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analytical Study

1.5 Who is This Report For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Company Name Reports

1.9 About Visiongain

2. Introduction to the World Influenza Vaccine Market

2.1 The Influenza Virus Kills over 500,000 People Every Year

2.2 Influenza has a Huge Social and Economic Burden on all Societies

2.3 The Influenza Virus Mutates Annually Rendering the Previous Year’s Vaccines Ineffective

2.3.1 All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)

2.3.2 The Antigenic Drift Mutation Causes Epidemics

2.3.3 The Antigenic Shift Mutation Causes Pandemics

2.4 An Epidemic or a Pandemic Outbreak?

2.4.1 Seasonal Influenza Epidemic (Local)

2.4.2 Pandemic Influenza (Worldwide): ‘A’ Subtype

2.4.3 Flu Vaccine Effectiveness

2.5 Key Influencers of the Influenza Vaccine Market

2.5.1 Governments and International Organisations

2.5.1.1 Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus

2.5.1.2 The Governmental Stance of the Importance of Influenza Directly Drives the Market

2.5.1.3 The WHO’s “Influenza Vaccine Production Transfer Project” Affects Big Pharma’s Vaccine Sales

2.5.2 Leading Manufacturers

2.5.2.1 Sanofi Pasteur is the Market Leader

2.5.2.2 CSL Has Bought Novartis’s Flu Vaccine Business Forming a New Influenza Vaccine Company Seqirus

2.5.2.3 GSK is Now Third Placed in the Market

2.5.2.4 AstraZeneca’s Flumist Product is in Trouble

3. Influenza Vaccine World Market Outlook, 2018-2028

3.1 The World Influenza Market Performance, 2017

3.1.1 Growing Elderly Population

3.1.2 Paediatric Influenza Vaccines – High Demand Markets

3.1.3 Emerging Markets

3.2 The World Influenza Market Revenue Forecast for 2018-2028

3.3 The World Influenza Market: Industry Trends, 2018-2028

3.3.1 Demand Driven Trends

3.3.2 Supply Efficiency Affects Sales

3.3.3 Funding Trends

3.3.4 Protecting the Workforce of an Economy

3.4 TIV Vaccines will be Replaced by QIV Vaccines in the Near Future

3.4.1 Trivalent Influenza Vaccines (TIV)

3.4.2 Quadrivalent Influenza Vaccines (QIV)

3.4.3 Influenza Vaccines by TIV and QIV Type

4. Global Influenza Vaccines Market By Vaccine Technology 2018-2028

4.1 The Influenza Vaccine Market Forecast 2018-2028, By Vaccine Technology (Trivalent and Quadrivalent)

5. Leading Influenza Vaccines 2018-2028

5.1 Sanofi Pasteur Influenza Vaccine Portfolio – Sales Forecast and Discussion 2018-2028

5.2 Seqirus Vaccine Portfolio – Sales Forecast and Discussion 2018-2028

5.3 GSK Influenza Vaccine Portfolio – Sales Forecast and Discussion 2018-2028

5.4 AstraZeneca Influenza Vaccine – Sales Forecast and Discussion 2018-2028

5.5 Protein Sciences Company Influenza Vaccine – Sales Forecast and Discussion 2018-2028

5.6 Other Vaccines: Sales Forecast and Discussion 2018-2028

6. Influenza Vaccines in Leading Developed Markets, 2018-2028

6.1 Influenza Vaccines: Leading Markets, 2018, 2023, 2028

6.1.1 Influenza Vaccine: Leading Developed Markets

6.2 The US Vaccine Market: 2018-2028

6.2.1 The US Vaccine Market: 2017

6.2.2 The US Vaccine Market Forecast: 2018-2028

6.2.3 Obama Healthcare Reform – the Benefits for Vaccine Sales

6.2.4 In the US Influenza Vaccines Come Equally from Manufacturers and Distributors

6.3 The Japanese Influenza Vaccine Market 2018-2028

6.3.1 The Japanese Vaccine Market 2017

6.3.2 The Japanese Vaccine Market Forecast 2018-2028

6.3.3 Filing the Vaccine Gap

6.3.4 Kaketsuken Loses Control of the Japanese Vaccine Market

6.4 The United Kingdom Influenza Vaccine Market 2018-2028

6.4.1 The UK Vaccine Market, 2017

6.4.2 The UK Vaccine Market, 2018-2028

6.4.3 Sanofi Pasteur’s QIV Vaccine is Authorized for use in the UK

6.5 The German Influenza Vaccine Market: 2018-2028

6.5.1 The German Vaccine Market, 2017

6.5.2 The German Vaccine Market: Forecast 2018-2028

6.6 The French Influenza Vaccine Market 2018-2028

6.6.1 The French Vaccine Market, 2017

6.6.2 The French Vaccine Market: Forecast 2018-2028

6.6.3 French Healthcare System – Events, Policies and Effects

6.6.4 The French Population Have the Highest Doubt over Vaccine Safety in Europe

6.7 The Italian Influenza Vaccine Market: 2018-2028

6.7.1 The Italian Vaccine Market: 2017

6.7.2 The Italian Vaccine Market Forecast: 2018-2028

6.7.3 Uncertain Foundation – Challenges in Public Healthcare

6.8 The Spanish Influenza Vaccine Market 2018-2028

6.8.1 The Spanish Vaccine Market: 2017

6.8.2 The Spanish Vaccine Market Forecast: 2018-2028

6.8.3 District Rules – Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2018-2028

7.1 Influenza Vaccines: Leading Markets, 2018, 2023, 2028

7.1.1 Influenza Vaccine: Leading Emerging National Markets

7.2 The Chinese Influenza Vaccine Market: 2018-2028

7.2.1 The Chinese Influenza Vaccine Market: 2017

7.2.2 The Chinese Influenza Vaccine Market Forecast: 2018-2028

7.2.3 High National Demand for Influenza Vaccines

7.3 The Indian Influenza Vaccine Market: 2018-2028

7.3.1 The Indian Vaccine Market: 2017

7.3.2 The Indian Influenza Vaccine Market Forecast: 2018-2028

7.3.3 Complications of Influenza Vaccines – How Much Progress Possible?

7.4 The Brazilian Influenza Vaccine Market: 2018-2028

7.4.1 The Brazilian Vaccine Market: 2017

7.4.2 The Brazilian Vaccine Market Forecast: 2018-2028

7.5 The Russian Vaccine Market: 2018-2028

7.5.1 The Russian Vaccine Market: 2017

7.5.2 The Russian Vaccine Market Forecast: 2018-2028

7.5.3 Power of the State

8. Research & Development Pipeline for Flu Vaccines

8.1 Seasonal Influenza Vaccines in Development

8.1.1 Sanofi Pasteur

8.1.1.1 Fluzone QIV High Dose

8.1.1.2 VaxiGrip QIV IM (6-35 months)

8.1.1.3 VaxiGrip QIV IM (3 years +)

8.1.2 Seqirus

8.1.2.1 MF59 QIV and TIV Vaccines

8.1.3 Takeda Pharmaceuticals

8.1.3.1 Takeda has Ceased Development of its TAK850 TIV Influenza Vaccine

8.1.4 Mitsubishi Tanabe Pharma

8.1.4.1 Plant Based Virus-Like- Particle Influenza Vaccine

8.2 Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2018- 2028

9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2017

9.1.1 Strengths

9.1.1.1 Ageing Population

9.1.1.2 Influenza Prevention is Crucial

9.1.1.3 Sales Growth in Emerging National Markets

9.1.1.4 Rising Awareness of the Disease

9.1.2 Weaknesses

9.1.2.1 Supply Chain Costs

9.1.2.2 Time Pressure

9.1.2.3 Barriers to Market Entry

9.1.3 Opportunities

9.1.3.1 Strong Research and Development Pipeline

9.1.3.2 Vaccine Delivery – Innovations and Opportunities for Improvements

9.1.3.3 Universal Flu Vaccine

9.1.3.4 Adult Vaccines – High Need

9.1.4 Threats

9.1.4.1 Productivity Gap

9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2017

9.2.1 Social Factors

9.2.1.1 Creating a Healthier Society

9.2.1.2 Public Fears of Side-Effects

9.2.2 Technological Forces

9.2.2.1 Advancements in Vaccine Technology

9.2.3 Economic Factors

9.2.3.1 Cost and Time Restraints

9.2.3.2 Emerging Markets Create Demand

9.2.4 Political Factors

9.2.4.1 Influence of Governments


10. Conclusions

10.1 Prevention of Influenza by Use of Flu Shots Rises in Importance

10.2 Japan as a Rising Consumer in the World Influenza Vaccine Market

10.3 Brazil and India Show Robust Growth

10.4 Emergence of a Universal Flu Vaccine

10.5 The US to Retain its Dominance

10.6 Concluding Remarks


Appendix A

About Visiongain

Associated Reports

Report Sales Order Form



Appendix B

Report Evaluation Form



Table of Tables

Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028

Table 2.1 Influenza Vaccine Effectiveness (%) 2004/5-2015/6

Table 3.1 World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 3.2 The World Market for Influenza Vaccines by Pharmaceutical Companies and ‘Others’; Revenue Forecast ($m), AGR (%) Market Share (%), 2018- 2028

Table 3.3 Influenza Vaccines Divided into TIV and QIV Type, 2017

Table 4.1 The Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028, by Vaccine Technology

Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2015

Table 5.2 Fluzone/VaxiGrip: Revenue ($m), 2013-2015

Table 5.3 Sanofi Pasteur (Fluzone/VaxiGrip); Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 5.4 Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 5.5 Fluarix/FluLaval: Revenue ($m), 2013-2015

Table 5.6 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2018-2028

Table 5.7 FluMist/Fluenz: Revenue ($m), 2013-2015

Table 5.8 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 5.9 FluBlok Revenue ($m), 2013-2014

Table 5.10 FluBlok: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 5.11 Other Influenza Vaccines Forecast: ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028

Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028

Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028

Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2018-2028

Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028

Table 8.1 Seasonal Influenza Vaccines in Development, 2018

Table 8.2 Universal Influenza Vaccines in Development, 2018


Table of Figures

Figure 1.1 Influenza Vaccines Market Segmentation

Figure 3.1 Influenza Vaccine’s Market Share of Global Vaccines Industry (%), 2017

Figure 3.2 Growth in the Uptake of Influenza Vaccines, 1990-2015

Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2017

Figure 3.4 Influenza Vaccinations by Age, 2016

Figure 3.5 Influenza Vaccines: Market Share by Geographical Region, 2017

Figure 3.6 The World Market for Influenza Vaccines Divided into Pharma Companies and ‘Others’, 2018- 2028

Figure 3.7 Influenza Market Share (%) by Pharma Companies and ‘Others’: 2018 and 2028

Figure 3.8 World Influenza Vaccines Market: Drivers and Restraints, 2018-2028

Figure 4.1 The Global Influenza Vaccine Revenue Forecast ($m), 2018-2028, by Vaccine Technology

Figure 5.1. Seqirus Influenza Vaccines; Revenue Forecast ($m), 2018-2028

Figure 5.2. GSK Influenza Vaccines; Revenue Forecast ($m), 2018-2028

Figure 5.3 FluMist/ Fluenz: Revenue Forecast ($m), 2018-2028

Figure 5.4 FluBlok: Revenue Forecast ($m), 2018-2028

Figure 5.5 Other Influenza Vaccines: Revenue Forecast ($m), 2018-2028

Figure 6.1 Influenza Vaccine Market Share (%) by Country, 2018

Figure 6.2 Developed National Markets: Drivers and Restraints, 2018-2028

Figure 6.3 The US Influenza Vaccine Revenue Forecast ($m), 2018-2028

Figure 6.4 The Japanese Influenza Vaccine Revenue Forecast ($m), 2018-2028

Figure 6.5 The UK Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 6.6 The German Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 6.7 The French Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 6.8 The Italian Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 6.9 The Spanish Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 7.1 Emerging National Markets: Drivers and Restraints, 2018-2028

Figure 7.2 The Chinese Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 7.3 The Indian Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 7.4 The Brazilian Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 7.5 The Russian Influenza Vaccines Revenue Forecast ($m), 2018-2028

Figure 9.1 SWOT Analysis of the Influenza Vaccines Market, 2017

Figure 9.2 STEP Analysis of the Influenza Vaccines Market, 2017

★調査レポート[インフルエンザワクチンの世界市場] ( Global Influenza Vaccines Market Outlook 2018-2028 / VGN808048) 販売に関する免責事項
[インフルエンザワクチンの世界市場] ( Global Influenza Vaccines Market Outlook 2018-2028 / VGN808048) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆